Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
Completed · Phase 2 · Has a placebo group
Conditions studied: Cervical Cancer, Precancerous Condition
In brief
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of eflornithine may be an effective way to prevent the recurrence of or further development of cervical cancer. PURPOSE: Randomized phase II trial to determine the effectiveness of eflornithine in preventing cervical cancer in patients who have cervical intraepithelial neoplasia.
Key facts
- Study ID
- NCT00006079
- Run by
- M.D. Anderson Cancer Center
- People needed
- 150
- Starts
- 1998-06-19
- Expected to finish
- 2004-04-27
- Last updated by the study team
- 2018-10-25
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Women with newly diagnosed or recurrent CIN grade 2-3, involving an area 3times larger than the biopsy site. Patients must be > 18 years old, with a performance status less than or equal to 2 (Zubrod Scale) and a predicted life expectancy of greater than or equal to 12 months. Patients must have a medically safe form of contraception for the duration of the study. All patients must complete the of pretreatment evaluation, consent to colposcopy and cervical biopsy for histologic evaluation
You may not qualify if…
- Patients may not have had a prior malignancy.
Where it is running
- University of Texas - MD Anderson Cancer Center — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.